Nebenwirkungen · Pomalidomide Teva
Pomalidomide Teva 1 mg hard capsules Pomalidomide Teva 2 mg hard capsules Pomalidomide Teva 3 mg hard capsules Pomalidomide Teva 4 mg hard capsules · Abschnitt 4.8 · PDF-Seite 15
HOS-152583 · Präparat HOS-100789
Pomalidomide in combination with bortezomib and dexamethasone The most commonly reported blood and lymphatic system disorders were neutropenia (54.0%), thrombocytopenia (39.9%) and anaemia (32.0%). Other most frequently reported adverse reactions included peripheral sensory neuropathy (48.2%), fatigue (38.8%), diarrhoea (38.1%), constipation (38.1%), and oedema peripheral (36.3%). The most commonly reported Grade 3 or 4 adverse reactions were blood and lymphatic system disorders including neutropenia (47.1%), thrombocytopenia (28.1%) and anaemia (15.1%). The most commonly reported serious adverse reaction was pneumonia (12.2%). Other serious adverse reactions reported included pyrexia (4.3%), lower respiratory tract infection (3.6%), influenza (3.6%), pulmonary embolism (3.2%), atrial fibrillation (3.2%) and acute kidney injury (2.9%).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-01T10:30:00Z · SHA-256 3ab54e22d7d43396e292fa7f180836a63e26f28dcb2f9290cf9a99a3058c6c74 · Passage 7145b6996d911ee262903242d6fc7745edc4e406629d898711a612f621c274d6 · Zeichen 31–878 im Abschnitt